wnt/beta-catenin pathway required development leukemia stem cells aml
leukemia stem cells lscs capable limitless self-renewal responsible maintenance leukemia selective eradication lscs offer substantial therapeutic benefit interest identifying signaling pathways control development studied lscs mouse models acute myelogenous leukemia aml induced either coexpression hoxa9 meis1a oncogenes fusion oncoprotein mll-af9 show wnt/beta-catenin signaling pathway required self-renewal lscs derived either hematopoietic stem cells hsc differentiated granulocyte-macrophage progenitors gmp wnt/beta-catenin pathway normally active hscs gmp results suggest reactivation beta-catenin signaling required transformation progenitor cells certain oncogenes beta-catenin absolutely required self-renewal adult hscs thus targeting wnt/beta-catenin pathway may represent new therapeutic opportunity aml
